Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574414 | 0.86 | TSHR (0.58) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL464444 | 0.86 | TSHR (0.39) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL22851251 | 0.85 | TSHR (0.56) | TSHRCA12CA14KMT2ALMNA | |
| SCHEMBL27805170 | 0.83 | TSHR (0.54) | TSHRCA12CA14KMT2ALMNA | |
| SCHEMBL10045818 | 0.82 | EPHX2 (0.38) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL11186122 | 0.80 | GAA (0.50) | KMT2AALDH1A1GAAMGAMSI | |
| SCHEMBL1188784 | 0.80 | TSHR (0.48) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL4073058 | 0.77 | TSHR (0.50) | TSHRCA12CA14KMT2AMEN1 | |
| SCHEMBL14176533 | 0.77 | POLB (0.33) | GAA | |
| SCHEMBL18738818 | 0.77 | ALDH1A1 (0.43) | LMNAKDM4EALDH1A1MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2020-12-31 | — | — | US | disclosed |
| CN-111690695-A | Enzymatic microfluidic online synthesis method of 3-phenylaminopropylhydroxamic acid | 浙江工业大学 | 2020-09-22 | — | — | CN | disclosed |
| CN-110446737-A | Coating is formed by separated application polyisocyantates composition and crosslinking catalyst | COVESTRO DEUTSCHLAND AG | 2019-11-12 | — | — | CN | disclosed |
| CN-109890865-A | Production of plastics by catalytic crosslinking of blocked polyisocyanates | 科思创德国股份有限公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-109843961-A | The method and equipment for coating of coil and stsip of blocked polyisocyanate containing catalytic crosslinking | 科思创德国股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-8404670-B2 | Histamine H3 inverse agonists and antagonists and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060089479-A1 | Blocked biuretized isocyanates | COVESTRO LLC | 2006-04-27 | — | — | US | disclosed |
| EP-1650245-A1 | Biuretized polyisocyanates blocked with aralkylamines | Bayer MaterialScience LLC (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1021411-B1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LTD (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-6326386-B1 | ANTICOAGULANT | GLAXO GROUP LIMITED (GB) | 2001-12-04 | — | — | US | disclosed |
| EP-1021411-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-1997022589-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | TSHR 4810/4885CA12 2110/4885CA14 3418/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | TSHR 4810/4885CA12 2110/4885CA14 3418/4885 |
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | TSHR 3156/4885CA12 4622/4885CA14 4428/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | TSHR 4804/4885CA12 2246/4885CA14 3261/4885 |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | TSHR 4810/4885CA12 2110/4885CA14 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.